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Rhabdomyosarcoma (RMS) is the most common malig-
nancy in childhood soft tissue sarcoma. Multimodal treat-
ment is essential for RMS, and radiotherapy plays an 
important role. The 5- year failure- free survival (FFS) rates 
are 90%, 60–70%, and 20–30% for low- , intermediate- , 
and high- risk patients, respectively [1–5]. However, toxici-
ties of radiotherapy are a significant problem in pediatric 
patients [6]. This is a particular concern in RMS because 
the common sites are the head and neck and parame-
ningeal lesions, for which bone retardation and growth 
hormone deficiency after radiotherapy are severe problems 
[7]. Also, secondary cancer is an important issue in 
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Abstract
To evaluate preliminary results of proton radiotherapy (PRT) for pediatric pa-
tients with rhabdomyosarcoma (RMS). From 1987 to 2014, PRT was conducted 
as initial radiotherapy in 55 patients (35 males, 20 females, median age 5 years, 
range 0–19) with RMS at four institutes in Japan. Thirty- one, 18, and six pa-
tients had embryonal, alveolar, and other RMS, respectively. One, 11, 37, and 
six patients were in IRSG groups I, II, III, and IV, respectively, and the COG 
risk group was low, intermediate, and high for nine, 39, and seven patients, 
respectively. The irradiation dose was 36–60 GyE (median: 50.4 GyE). The me-
dian follow- up period was 24.5 months (range: 1.5–320.3). The 1- and 2- year 
overall survival rates were 91.9% (95% CI: 84.3–99.5%) and 84.8% (95% CI 
75.2–94.3%), respectively, and these rates were 100% and 100%, 97.1% and 
90.1%, and 57.1% and 42.9% for COG low- , intermediate- , and high- risk groups, 
respectively. There were 153 adverse events of Grade ≥3, including 141 hema-
tologic toxicities in 48 patients (87%) and 12 radiation- induced toxicities in 
nine patients (16%). Proton- specific toxicity was not observed. PRT has the 
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children. Proton radiotherapy (PRT) is likely to reduce 
these toxicities compared to photon radiotherapy, and 
dosimetric advantages of PRT have been suggested for 
treatment of RMS [8, 9]. However, there are few clinical 
studies of PRT for RMS. Here, we evaluated preliminary 
results of PRT for RMS in a multicenter study in Japan.
Materials and Methods
A retrospective observational study of PRT was performed 
in 71 pediatric patients (aged <20 years old) with primary 
RMS treated at four institutions in Japan from 1987 to 
2014. Fifteen patients who received PRT for recurrent or 
secondary RMS were excluded from the study. One patient 
with multiple spinal metastases during PRT, in whom the 
treatment strategy was changed from local irradiation with 
PRT to craniospinal irradiation with photon radiotherapy, 
was also excluded, leaving 55 patients for analysis. The 
study was approved by each Institutional Review Board. 
We have previously reported an overview of this study 
[10, 11], in which we mainly analyzed overall survival and 
late toxicities of all patients and long- term survivors. Multiple 
tumor types were also included in the analysis, and so 
details for specific tumors were unclear. To properly define 
the treatment outcomes of PRT for RMS, we performed 
a secondary analysis focused only on patients with RMS.
Statistical analysis
The primary endpoints of this study are overall survival 
(OS), progression- free survival (PFS), and local control 
rate (LCR) estimated using the Kaplan–Meier method, 
and the secondary endpoint is acute adverse effects of 
PRT. OS, PFS, and LCR were measured from the start 
of PRT until the respective event, including death for OS 
and tumor progression at the primary site for LCR. A 
log- rank test was used to evaluate differences in OS, PFS, 
and LCR among three risk groups based on COG criteria 
at the time the study protocol was written. All analyses 
were performed with SPSS ver. 11.0 (SPSS Inc., Chicago, 
IL). Toxicities were graded using the Common Terminology 
Criteria for Adverse Events ver. 3.0.
Results
A total of 55 patients (35 males and 20 females) (Table 1) 
had a median age at treatment of 5 years old (range: 0–19). 
Thirty- one patients had embryonal RMS, 18 had alveolar 
RMS, and six had another form of RMS. The irradiated 
sites were the head and neck (n = 37), parameningeal sites 
(n = 3), prostate (n = 8), and others (n = 7). One, 11, 
37, and six patients were classified into IRSG surgicopatho-
logic groups I, II, III, and IV, respectively, and the COG 
risk group was low, intermediate, and high for nine, 39, 
and seven patients, respectively. The irradiation dose ranged 
from 36 to 60 GyE (median: 50.4 GyE). Surgical resection 
before PRT was performed in 41 patients (75%), and 53 
patients (96%) received chemotherapy: pre- PRT, pre- and 
during PRT, and only during PRT in 17, 34, and two 
patients, respectively. The median follow- up period in all 
55 patients was 24.5 months (range: 1.5–320.3 months), 
and 11 patients were followed up for ≥5 years.
At final follow- up, the 1- and 2- year OS rates were 
91.9% (95% CI: 84.3–99.5%) and 84.8% (95% CI: 75.2–
94.3%), respectively, and the 1- and 2- year PFS rates were 
81.6% (95% CI: 70.7–92.5%) and 72.4% (95% CI: 59.6–
85.3%), respectively. Nine patients died: seven due to tumor 
progression, one due to secondary cancer, and one due 
to a non- tumor- related cause. Thirteen patients had recur-
rence, including five with local recurrence and eight with 
distant metastases. The 1- and 2- year LCRs were 95.6% 
(95% CI: 89.6–100%) and 93.0% (95% CI: 85.3–100%), 
respectively (Fig. 1). In the COG low- , intermediate- , and 
high- risk groups, the 1- and 2- year LCRs were 100% and 
100%, 96.8% and 96.8%, and 80.0% and 53.3%, respec-
tively. LCRs were significantly poor at high- risk group 
(P = 0.009). The 1- and 2- year OS rates were 100% and 
100%, 97.1% and 90.1%, and 57.1% and 42.9%, respec-
tively (Fig. 2). OS was significantly poor at high- risk group 
(P = 0.001). And the 1- and 2- year PFS rates were 85.7% 
and 85.7%, 88.2% and 81.8%, and 42.9% and 14.3%, 
Table 1. Patients and PBT characteristics (n = 55).
Item Value























1872 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
M. Mizumoto et al.PRT for Pediatric Rhabdomyosarcoma
respectively. PFS was also significantly poor at high- risk 
group (P = 0.001).
At first, we focused on acute toxicities (Table 2). There 
were a total of 153 acute toxicities of Grade ≥3: 141 
hematologic toxicities in 48 patients (87%) and 12 
radiation- induced toxicities (including mucositis and der-
matitis) in nine patients (16%). At the start of PRT, 60 
hematologic toxicities were present due to previous treat-
ment. Changes in hematologic toxicities from the start 
of PRT to maximum toxicity during PRT are that 23 
(42%), 34 (62%), and 33 (60%) patients had exacerbation 
of anemia, decreased white blood cells, and decreased 
neutrophil count, respectively. In 19 patients who received 
PRT without concurrent chemotherapy, exacerbation of 
these events occurred in four (21%), nine (47%), and 
seven (37%), respectively. For patients who received con-
current chemotherapy, similar exacerbation occurred in 
19 (53%), 25 (69%), and 26 (72%), respectively.
As for late toxicities, eight patients experienced nine 
Grade 2 late toxicities. Six were deformity, and three were 
others (chronic otitis, growth hormone deficiency, and 
hearing impairment). Grade 3 or more late toxicities were 
not occurred. All Grade 2 late toxicities were occurred 
in the patients with head and neck or parameningeal 
tumor, and seven of 10 patients, who survive 5 years or 
more, experienced Grade ≥2 late toxicities.
Discussion
In this analysis, the short median follow- up period allowed 
evaluation of only short- term treatment outcomes and 
toxicities. In the low- , intermediate- , and high- risk groups, 
the 2- year OS rates were 100%, 90%, and 42.9%, and 
the 2- year PFS rates were 85.7%, 81.8%, and 14.3%, 
respectively. In the COG trial, the respective 2- year OS/
FFS rates were 95–100%/85–90%, 80–90%/70–80%, and 
40–50%/20–30% (with chemotherapy) [1–5]. Our results 
are similar to these findings. In Japan, PRT is mainly 
used to reduce late toxicity, and treatment for RMS is 
normally based on photon radiotherapy [12, 13, Fig. 3]. 
Our results indicate that PRT can achieve the same treat-
ment outcomes as photon radiotherapy. Two recent reports 
of PRT for RMS also showed similar results. In preliminary 
results of a phase II trial of PRT for RMS, Ladra et al. 
[14] found 2- year OS rates of 100% and about 80% for 
low- and intermediate- risk patients, respectively. In the 
largest clinical study of PRT performed to date, in 83 
patients (risk: low 20, intermediate 52, high 11), Leiser 
et al. [15] found 2- year OS rates of 80- 90% after PRT. 
Both reports also concluded that PRT gives similar out-
comes compared to treatment with photon radiation.
Our analysis showed a low rate of radiation- related 
acute toxicity of Grade ≥3 of 16% and good recovery 
after PRT. Most patients (87%) had hematologic toxicities 
of Grade ≥3, and it is difficult to determine which treat-
ment (chemotherapy, surgery, or radiotherapy) caused this 
toxicity. However, the risk of exacerbation of hematologic 
toxicities during PRT was twice as high in patients 
Figure 1. Overall survival (OS), progression- free survival (PFS), and local 
control (LC) rates in all patients.
Figure 2. Overall survival rate according to COG risk group.
Table 2. Acute toxicities of Grade 3 or higher.
Toxicity Grade 3 Grade 4




White blood cell decreased 5 39
Neutrophil count decreased 5 35
Plate count decreased 9 12
Electrolyte abnormality 2 1
GOT/GPT increased 2 0
Blood bilirubin increased 0 0
Others 2 0
Others: Infection.
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receiving concurrent chemotherapy (anemia 53%, white 
blood cells 69%, neutrophils 72%) than those treated with 
nonconcurrent chemotherapy (anemia 21%, white blood 
cells 47%, neutrophils 37%). Arndt et al. [3] found rates 
of Grade 3 or 4 acute toxicity in treatment of intermediate- 
risk RMS of about 80% (neutropenia) and 50% (anemia). 
In our analysis, the schedule of chemotherapy was 
unknown, but the risk of acute hematologic toxicity looks 
similar. In a recent study of Grade 3 and Grade 4 acute 
toxicity after irradiation in children, Pixberg et al. [16] 
reported acute toxicity rates of 63.8% in bone marrow, 
7.6% in skin, and 7.6% in mucosa. These rates are also 
similar to our data for skin three of 55 (5.5%) and mucosa 
five of 55 (9.1%). Additionally, in multivariate analysis, 
Pixberg et al. [16] showed that concomitant chemotherapy 
was a risk factor for acute toxicity, and our results show 
a similar trend. In patients with head and neck RMS 
treated by PRT, Ladra et al. showed acute toxicity rates 
of 6–8% for Grade 3 dermatitis and 3% for mucositis, 
with a total Grade 3 rate of 17%, which is close to our 
rate of 16%. At this time, follow- up period was still short, 
but all Grade 2 or more late toxicities occurred for head 
and neck or parameningeal tumor. This looks same ten-
dency that we reported previously. The most likely benefit 
of PRT is to reduce late toxicity, but obtaining these data 
will require longer follow- up in more patients. However, 
our results indicate that PRT can achieve the same short- 
term treatment effect as photon radiotherapy with tolerable 
acute radiation- induced toxicity.
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